Table 1.
Sample characteristics at baseline
| Characteristics | DCS (n=34) | Placebo (n=33) | p-value |
|---|---|---|---|
| Demographics | |||
| Age (years), mean (SD) | 8.38 (1.93) | 8.25 (1.73) | .76 |
| Sex, n (%) male | 28 (82.35) | 27 (81.82) | .95 |
| Clinical Variables | |||
| Stanford-Binet V, mean (SD) | |||
| Full Scale IQ | 92.42 (17.76) | 87.30 (15.74) | .22 |
| NonVerbal IQ | 95.15 (18.03) | 90.82 (15.19) | .30 |
| Verbal IQ | 90.85 (18.97) | 85.45 (16.83) | .23 |
| VABS-II Expressive Language subscale standard score, mean (SD) | 87.38 (13.36) | 84.55 (14.94) | .42 |
| Clinical Global Impression-Severity | 4.03 (0.18) | 4.06 (0.24) | .58 |
| Diagnosis, n (%) | |||
| PDD-NOS | 12 (35.29) | 15 (45.45) | .40 |
| Autistic Disorder | 3 (8.82) | 5 (15.15) | .48a |
| Asperger’s Disorder | 19 (55.88) | 13 (39.39) | .18 |
| Concomitant medications, n (%) | |||
| Antipsychotics | 8 (23.53) | 8 (24.24) | .95 |
| Alpha-2 Agonists | 6 (17.65) | 8 (24.24) | .51 |
| Stimulants | 14 (41.18) | 11 (33.33) | .51 |
| Sleep Aids | 9 (26.47) | 7 (21.21) | .61 |
| Mood Stabilizers | 1 (2.94) | 2 (6.06) | .61a |
| Glutamatergic Modulators | 1 (2.94) | 0 (0.00) | 1.00a |
| Other | 3 (8.82) | 1 (3.03) | .61a |
| Concomitant treatment, n (%) | |||
| Speech Therapy | 19 (55.88) | 16 (51.52) | .72 |
| Occupational Therapy | 12 (35.29) | 15 (45.45) | .40 |
| Behavioral Therapy | 9 (26.47) | 9 (27.27) | .94 |
| Other Psychotherapy | 1 (2.94) | 2 (6.06) | .61a |
| Physical Therapy | 0 (0.00) | 2 (6.06) | .24a |
| Social Skills Training | 3 (8.82) | 2 (6.06) | 1.00a |
| Music Therapy | 0 (0.00) | 1 (3.03) | .49a |
| Other Treatments | 3 (8.82) | 0 (0.00) | .24a |
a: Fisher’s Exact Test